NCT02810886View on ClinicalTrials.gov

Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management

PHASE2WithdrawnINTERVENTIONAL

Timeline

Start Date

October 31, 2016

Primary Completion Date

January 20, 2017

Study Completion Date

January 20, 2017

Conditions

Prostate Cancers

Interventions

DRUG

68Ga-(HBED-CC)-PSMA

68Ga-PSMA-ligand intravenous administration duration is around one minute. Once the patient is injected, the tracer needs 60 minutes to be evenly distributed through the body. PET/CT images will then be performed.